Faruqi & Faruqi, LLP Launches An Investigation Against Ocera Therapeutics, Inc. (OCRX) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Ocera Therapeutics, Inc. (“Ocera” or the “Company”) (NasdaqGM: OCRX) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for the Ocera Therapeutics, Inc. Second Amended and Restated 2011 Stock Option and Incentive Plan.
Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on November 15, 2013, the Board of Directors recommends that Ocera’s shareholders vote to approve the Ocera Therapeutics, Inc. Second Amended and Restated Option and Incentive Plan to increase the number of shares by 2,000,000 to 2,302,328. The issuance of the additional shares could have a substantial dilutive effect on the shares of Ocera common stock.
If you own common stock in Ocera and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.